+

Webinars & Podcasts

Listen again to our industry experts providing analysis and insight on what you need for successful development and commercialization of testing for targeted therapies
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about biomarkers and diagnostic testing, where they look for information and what gaps they feel need to be addressed to better arm them with the right...
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value....
Has Next Generation Sequencing lived up to the hype of industry predictions? Join our next webinar to get a unique insight into the real-world use of NGS in the clinical setting. What are the opportunities and challenges of its implementation and how will this affect future adoption and utility? This collaborative discussion between Diaceutics and NeoGenomics Laboratories will shed light on...
Implementation of biomarker testing is key to the success of precision medicine. The success of therapies based on immuno-oncology, with over six indications in recent years (predominantly lung cancer), has highlighted the need for PD-L1 biomarker testing and the challenges it raises for implementation. In this webinar, we will discuss the adoption of PD-L1 testing in Europe using Germany and...
For the 2017 Pharma Readiness for Dx Index, Diaceutics applies analyses to 23 companies and examines the precision medicine (PM) credentials of over 1000 therapies on the market and in the pipeline, providing a 360° view of Dx-dependent therapy (Rx) assets. We include Big Data and lab partnerships alongside Rx/Dx partnerships to reflect the evolution of PM beyond molecular testing? and make...
To date, multiple PD-L1 therapies have been launched – some with a diagnostic test in-label and some not. For those therapies that require testing, we will highlight how test adoption can be optimized. Listen to the webinar to learn: 10 years of personalized medicine evidence-based insights from Diaceutics The latest in data and research on PD-L1 testing, adoptions, kits and labels How to...
For the most part, personalized medicine and targeted therapies have been focused on oncology. However, there is new and exciting activity outside of oncology where biomarker and targeted approaches are proving successful.  This webinar provides insights on those non-oncology therapeutic areas to watch and the data available to support your your targeted therapy launch. Listen to the webinar...
Targeted therapy communications present a host of new opportunities and challenges for brand teams. Research has shown that positive diagnostic sentiment among consumers can be leveraged to enhance and optimize targeted therapy communications. But until now no reports have studied the communication styles pharma has used in targeted therapy communications. This webinar, led by the Bioceutics...
Will you be launching a targeted therapy in the next 24 to 48 months? This Labceutics webinar provides key insights into laboratory strategy, data and key market landscape differences when planning for a targeted therapy launch. Join an expert panel of targeted therapy and laboratory data experts to hear about the ‘forgotten’ but critical stakeholder in successful global targeted...
Are you planning to launch a diagnostic alongside a targeted therapy in the next 18-24 months. This webinar highlights Diaceutics’ recent PD-L1 lost therapy opportunity assessment, which demonstrated that every $1 spent on smart diagnostic efficiency returns between $20-$40 in additional therapy revenues otherwise lost. It also highlights how effective diagnostic planning can maximize...
Will you be launching a targeted therapy in the next 24 to 48 months? This Labceutics webinar provides key insights into laboratory strategy, data and key market landscape differences when planning for a targeted therapy launch. Join an expert panel of targeted therapy and laboratory data experts to hear about the ‘forgotten’ but critical stakeholder in successful global targeted...
A forecast for the industry raises some interesting points. Will there be 50 per cent more targeted therapy launches in 2016? Are labs becoming the key pharma launch partners? Are payer value models finally get some traction? And how will companion and complementary diagnostics be defined? Listen to this webinar to learn: Insights on the latest trends in targeted therapies Best practices for...

Latest Blogs

Blogs

Expert Insights

The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that...
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the...

Competitive Benchmarking Reports

Pharma Precision Medicine Readiness Report 2019
PM Readiness Report 2018 Summary

Publications

FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with >5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved...
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of...
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about biomarkers and diagnostic testing, where they look for information and what gaps they feel need to be addressed to better arm them with the right...
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value....
Has Next Generation Sequencing lived up to the hype of industry predictions? Join our next webinar to get a unique insight into the real-world use of NGS in the clinical setting. What are the opportunities and challenges of its implementation and how will this affect future adoption and utility? This collaborative discussion between Diaceutics and NeoGenomics Laboratories will shed light on...
Implementation of biomarker testing is key to the success of precision medicine. The success of therapies based on immuno-oncology, with over six indications in recent years (predominantly lung cancer), has highlighted the need for PD-L1 biomarker testing and the challenges it raises for implementation. In this webinar, we will discuss the adoption of PD-L1 testing in Europe using Germany and...
For the 2017 Pharma Readiness for Dx Index, Diaceutics applies analyses to 23 companies and examines the precision medicine (PM) credentials of over 1000 therapies on the market and in the pipeline, providing a 360° view of Dx-dependent therapy (Rx) assets. We include Big Data and lab partnerships alongside Rx/Dx partnerships to reflect the evolution of PM beyond molecular testing? and make...
To date, multiple PD-L1 therapies have been launched – some with a diagnostic test in-label and some not. For those therapies that require testing, we will highlight how test adoption can be optimized. Listen to the webinar to learn: 10 years of personalized medicine evidence-based insights from Diaceutics The latest in data and research on PD-L1 testing, adoptions, kits and labels How to...
For the most part, personalized medicine and targeted therapies have been focused on oncology. However, there is new and exciting activity outside of oncology where biomarker and targeted approaches are proving successful.  This webinar provides insights on those non-oncology therapeutic areas to watch and the data available to support your your targeted therapy launch. Listen to the webinar...
Targeted therapy communications present a host of new opportunities and challenges for brand teams. Research has shown that positive diagnostic sentiment among consumers can be leveraged to enhance and optimize targeted therapy communications. But until now no reports have studied the communication styles pharma has used in targeted therapy communications. This webinar, led by the Bioceutics...
Will you be launching a targeted therapy in the next 24 to 48 months? This Labceutics webinar provides key insights into laboratory strategy, data and key market landscape differences when planning for a targeted therapy launch. Join an expert panel of targeted therapy and laboratory data experts to hear about the ‘forgotten’ but critical stakeholder in successful global targeted...
Are you planning to launch a diagnostic alongside a targeted therapy in the next 18-24 months. This webinar highlights Diaceutics’ recent PD-L1 lost therapy opportunity assessment, which demonstrated that every $1 spent on smart diagnostic efficiency returns between $20-$40 in additional therapy revenues otherwise lost. It also highlights how effective diagnostic planning can maximize...
Will you be launching a targeted therapy in the next 24 to 48 months? This Labceutics webinar provides key insights into laboratory strategy, data and key market landscape differences when planning for a targeted therapy launch. Join an expert panel of targeted therapy and laboratory data experts to hear about the ‘forgotten’ but critical stakeholder in successful global targeted...
A forecast for the industry raises some interesting points. Will there be 50 per cent more targeted therapy launches in 2016? Are labs becoming the key pharma launch partners? Are payer value models finally get some traction? And how will companion and complementary diagnostics be defined? Listen to this webinar to learn: Insights on the latest trends in targeted therapies Best practices for...
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about biomarkers and diagnostic testing, where they look for information and what gaps they feel need to be addressed to better arm them with the right...
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value....
Has Next Generation Sequencing lived up to the hype of industry predictions? Join our next webinar to get a unique insight into the real-world use of NGS in the clinical setting. What are the opportunities and challenges of its implementation and how will this affect future adoption and utility? This collaborative discussion between Diaceutics and NeoGenomics Laboratories will shed light on...
Implementation of biomarker testing is key to the success of precision medicine. The success of therapies based on immuno-oncology, with over six indications in recent years (predominantly lung cancer), has highlighted the need for PD-L1 biomarker testing and the challenges it raises for implementation. In this webinar, we will discuss the adoption of PD-L1 testing in Europe using Germany and...
For the 2017 Pharma Readiness for Dx Index, Diaceutics applies analyses to 23 companies and examines the precision medicine (PM) credentials of over 1000 therapies on the market and in the pipeline, providing a 360° view of Dx-dependent therapy (Rx) assets. We include Big Data and lab partnerships alongside Rx/Dx partnerships to reflect the evolution of PM beyond molecular testing? and make...
To date, multiple PD-L1 therapies have been launched – some with a diagnostic test in-label and some not. For those therapies that require testing, we will highlight how test adoption can be optimized. Listen to the webinar to learn: 10 years of personalized medicine evidence-based insights from Diaceutics The latest in data and research on PD-L1 testing, adoptions, kits and labels How to...
For the most part, personalized medicine and targeted therapies have been focused on oncology. However, there is new and exciting activity outside of oncology where biomarker and targeted approaches are proving successful.  This webinar provides insights on those non-oncology therapeutic areas to watch and the data available to support your your targeted therapy launch. Listen to the webinar...
Targeted therapy communications present a host of new opportunities and challenges for brand teams. Research has shown that positive diagnostic sentiment among consumers can be leveraged to enhance and optimize targeted therapy communications. But until now no reports have studied the communication styles pharma has used in targeted therapy communications. This webinar, led by the Bioceutics...
Will you be launching a targeted therapy in the next 24 to 48 months? This Labceutics webinar provides key insights into laboratory strategy, data and key market landscape differences when planning for a targeted therapy launch. Join an expert panel of targeted therapy and laboratory data experts to hear about the ‘forgotten’ but critical stakeholder in successful global targeted...
Are you planning to launch a diagnostic alongside a targeted therapy in the next 18-24 months. This webinar highlights Diaceutics’ recent PD-L1 lost therapy opportunity assessment, which demonstrated that every $1 spent on smart diagnostic efficiency returns between $20-$40 in additional therapy revenues otherwise lost. It also highlights how effective diagnostic planning can maximize...
Will you be launching a targeted therapy in the next 24 to 48 months? This Labceutics webinar provides key insights into laboratory strategy, data and key market landscape differences when planning for a targeted therapy launch. Join an expert panel of targeted therapy and laboratory data experts to hear about the ‘forgotten’ but critical stakeholder in successful global targeted...
A forecast for the industry raises some interesting points. Will there be 50 per cent more targeted therapy launches in 2016? Are labs becoming the key pharma launch partners? Are payer value models finally get some traction? And how will companion and complementary diagnostics be defined? Listen to this webinar to learn: Insights on the latest trends in targeted therapies Best practices for...

Blogs

Expert Insights

The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that...
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the...

Competitive Benchmarking Reports

Pharma Precision Medicine Readiness Report 2019
PM Readiness Report 2018 Summary

Publications

FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with >5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved...
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of...